CYB5D2 requires heme-binding to regulate HeLa cell growth and confer survival from chemotherapeutic agents.
The cytochrome b5 domain containing 2 (CYB5D2; Neuferricin) protein has been reported to bind heme, however, the critical residues responsible for heme-binding are undefined. Furthermore, the relationship between heme-binding and CYB5D2-mediated intracellular functions remains unknown. Previous stud...
Main Authors: | Anthony Bruce, Adrian P Rybak |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3899279?pdf=render |
Similar Items
-
Dataset on the effects of CYB5D2 on the distribution of HeLa cervical cancer cell cycle
by: Yanyun Xie, et al.
Published: (2016-03-01) -
Art-Id/Cyb-Id
by: Josep Giribet
Published: (2007-01-01) -
Effect of Gallic acid in potentiating chemotherapeutic effect of Paclitaxel in HeLa cervical cancer cells
by: Nora M. Aborehab, et al.
Published: (2019-06-01) -
Revisiting HeLa
by: Obiora Anekwe
Published: (2014-03-01) -
Crucial role of heme oxygenase-1 on the sensitivity of cholangiocarcinoma cells to chemotherapeutic agents.
by: Sarinya Kongpetch, et al.
Published: (2012-01-01)